PERFECT(Paliperidone Extended Release(ER)ER efFECTiveness Study to Evaluate the Objective Symptom Change and Symptomatic Remission)

• To examine whether the symptom is improved or changed after switching from the previous oral antipsychotic to flexibly dosed paliperidone ER. The primary endpoints are the changes in total and partial score of positive and negative symptoms(PANSS) [ Time Frame: During this study(48 weeks), primary outcome will be measered 10 time (Baseline, 1-week, 2-week, 4-week, 8-week, 12-week, 16-week, 24-week, 36-week, 48-week) ] [ Designated as safety issue: No ]
  

• Various variables will be investigated to evaluate responses : the 8-item of PANSS for schizophrenia for remission [ Time Frame: During this study(48 weeks), secondary outcomes will be measured 10 time (Baseline, 1-week, 2-week, 4-week, 8-week, 12-week, 16-week, 24-week, 36-week, 48-week) ] [ Designated as safety issue: No ]
  

This is an open-label, prospective, single arm, 48-week, non-comparative study, starting with paliperidone ER that is aiming to investigate the safety and effectiveness of flexibly dosed paliperidone ER in 252 patients with schizophrenia.

This study will examine long-term effectiveness and safety on the multidimensional aspects (objective and subjective symptoms) after switching from the existing drug to paliperidone Extended Release(ER) in patients with schizophrenia which is not controlled by the existing drug. This study has a limit in that it is designed as an open-label study, but can find the use pattern of paliperidone ER, which its effectiveness was already proven, in clinical practice because it targets representative patients. This study also will be useful data for clinicians because it will evaluate the effectiveness including remission rates in case of a long-term treatment. The study will especially classify the causes of failure for the existing antipsychotic therapies and inspect effectiveness and safety of paliperidone ER and whether those failures can be resolved. This study is more meaningful in that it will apply the remission criteria in patients with schizophrenia defined by Andreasen et al. in 2005 for the purpose of evaluating long-term therapeutic effectiveness.

The primary objective of this study is to examine whether the symptom is improved or changed after switching from the previous oral antipsychotic to flexibly dosed paliperidone ER. The primary endpoints are the changes in total and partial score of positive and negative symptoms (PANSS). The secondary objectives of the study are as follows; (1) Various variables will be investigated to evaluate responses after switching from previous oral antipsychotic medication to flexibly dosed paliperidone ER : Assessment of the 8-item of PANSS for schizophrenia for remission, General measures of treatment success, symptom check list-90-revised(SCL-90-R), Personal and social functioning, subject's Executive Function, subjective well-being of patients taking Neuroleptics.;(2)To explore the tolerability and safety of paliperidone ER, following variables will be assessed : vital signs, Drug-Induced Extrapyramidal Symptoms Scale, Liverpool University neuroleptic side effect rating scale (LUNSERS), weight and circumference of waist, clinical Laboratory test and adverse events (AEs) The recommended dose of paliperidone Extended Release(ER) oral tablet is 6 mg once daily. For some patients, the dose can be increased or decreased within the recommended range of 3 to 12 mg. During the study period(24 week), the flexible dose of paliperidone ER within a range of 3 to 12 mg can be administered daily. Since this study is a flexible-dose study, the investigator can adjust the dose proper to each patient.